Glaukos Corporation (GKOS) Misses Q3 EPS by 7c; Raises Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. ARM
4. BROS
5. QCOM
6. EXPE
7. PAYC
8. APP
9. FSLY
10. CPAY

Go back to Glaukos Corporation (GKOS) Misses Q3 EPS by 7c; Raises Revenue Outlook

Glaukos Corporation Announces Third Quarter 2018 Financial Results

November 7, 2018 4:10 PM EST

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2018. Key highlights include:

Achieved 9% net sales growth to $43.9 million in the third quarter of 2018, compared to $40.4 million in the third quarter of 2017. Reported gross margin of approximately 86% in the third quarter of 2018, compared to approximately 86% in the third quarter of 2017.... More